IDEXX Laboratories Company Profile (NASDAQ:IDXX)

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Medical Equipment & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:IDXX
  • CUSIP: 45168D10
  • Web:
  • Market Cap: $14.68313 billion
  • Outstanding Shares: 88,123,000
Average Prices:
  • 50 Day Moving Avg: $164.57
  • 200 Day Moving Avg: $151.47
  • 52 Week Range: $92.52 - $173.01
  • Trailing P/E Ratio: 61.73
  • Foreward P/E Ratio: 47.88
  • P/E Growth: 3.14
Sales & Book Value:
  • Annual Revenue: $1.82 billion
  • Price / Sales: 8.07
  • Book Value: ($0.84) per share
  • Price / Book: -198.36
  • EBIDTA: $449.79 million
  • Net Margins: 13.47%
  • Return on Equity: -706.91%
  • Return on Assets: 15.74%
  • Debt-to-Equity Ratio: -8.05%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.75%
  • Average Volume: 636,190 shs.
  • Beta: 0.48
  • Short Ratio: 3.4
Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories announced that its Board of Directors has approved a stock buyback program on Sunday, June 4th 2017, which allows the company to repurchase 3,000,000 shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its earnings results on Friday, April, 28th. The company reported $0.77 EPS for the quarter, topping the Zacks' consensus estimate of $0.61 by $0.16. The business had revenue of $462 million for the quarter, compared to the consensus estimate of $455.10 million. IDEXX Laboratories had a net margin of 13.47% and a negative return on equity of 706.91%. IDEXX Laboratories's revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.51 EPS. View IDEXX Laboratories' Earnings History.

When will IDEXX Laboratories make its next earnings announcement?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for IDEXX Laboratories.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

6 analysts have issued 1 year price targets for IDEXX Laboratories' stock. Their forecasts range from $118.00 to $185.00. On average, they anticipate IDEXX Laboratories' stock price to reach $161.00 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.

What are analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
  • Jay Mazelsky, Executive Vice President
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
  • William T. End, Lead Independent Director
  • Bruce L. Claflin, Independent Director
  • Rebecca M. Henderson Ph.D., Independent Director
  • Daniel M. Junius, Independent Director
  • Lawrence D. Kingsley, Independent Director

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.40%), Ardevora Asset Management LLP (0.27%), First Quadrant L P CA (0.24%), Bourne Lent Asset Management Inc. (0.13%), GW&K Investment Management LLC (0.11%) and Barometer Capital Management Inc. (0.10%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Capital Investment Services of America Inc., Ardevora Asset Management LLP, First Quadrant L P CA, Meeder Asset Management Inc., Bourne Lent Asset Management Inc., Headinvest LLC, Barometer Capital Management Inc. and Wendell David Associates Inc.. Company insiders that have sold IDEXX Laboratories stock in the last year include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Mn Services Vermogensbeheer B.V., Oregon Public Employees Retirement Fund, Bedrijfstakpensioenfonds Voor DE Media PNO, National Pension Service, Aperio Group LLC, Hermes Investment Management Ltd. and Nisa Investment Advisors LLC. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $166.62.

MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  315
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $161.00 (3.37% downside)

Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017Stifel NicolausReiterated RatingBuy$185.00LowView Rating Details
6/13/2017Canaccord GenuityReiterated RatingBuy$180.00LowView Rating Details
5/31/2017AegisInitiated CoverageSell$118.00LowView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
9/29/2016Bank of America CorporationReiterated RatingNeutralN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
4/1/2016CL KingInitiated CoverageNeutralN/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/28/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for IDEXX Laboratories (NASDAQ:IDXX)
Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Earnings History by Quarter for IDEXX Laboratories (NASDAQ IDXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.83
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.72$0.76$0.74
Q4 20173$0.59$0.67$0.64
(Data provided by Zacks Investment Research)


Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 89.04%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.00View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
DateHeadline logoIDEXX Laboratories, Inc. (NASDAQ:IDXX) Upgraded to "Buy" at Zacks Investment Research - July 23 at 11:50 PM logoIDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards? - Nasdaq - July 21 at 4:17 PM logoThese Non-Tech Companies Are Investing In An AI Future - July 21 at 4:17 PM logoIDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards? - July 21 at 4:17 PM logo Brokerages Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $500.78 Million - July 20 at 10:00 AM logoHead to Head Contrast: IDEXX Laboratories (NASDAQ:IDXX) & Heska Corporation (HSKA) - July 18 at 8:24 PM logoIDEXX Laboratories Elects Stuart M. Essig to Board of Directors - PR Newswire (press release) - July 17 at 8:45 PM logoIDEXX Laboratories Elects Stuart M. Essig to Board of Directors - July 17 at 8:45 PM logoHead-To-Head Survey: IDEXX Laboratories (IDXX) & Heska Corporation (HSKA) - July 16 at 10:29 PM logoHead to Head Survey: IDEXX Laboratories (IDXX) and Heska Corporation (HSKA) - July 16 at 8:12 PM logoStifel Nicolaus Reiterates Buy Rating for IDEXX Laboratories, Inc. (IDXX) - July 15 at 11:18 AM logoIDEXX Laboratories (IDXX) versus Heska Corporation (HSKA) Head to Head Comparison - July 15 at 10:08 AM logoComparing Heska Corporation (HSKA) & IDEXX Laboratories (IDXX) - July 15 at 9:02 AM logoFriday Sector Leaders: Healthcare, Utilities - Nasdaq - July 15 at 1:22 AM logoETFs with exposure to IDEXX Laboratories, Inc. : July 14, 2017 - July 15 at 1:22 AM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : July 13, 2017 - July 14 at 3:27 AM logoCritical Survey: IDEXX Laboratories (IDXX) & Heska Corporation (HSKA) - July 11 at 2:10 PM logoIDEXX Laboratories to Release 2017 Second Quarter Financial ... - PR Newswire (press release) - July 10 at 7:43 PM logoIDEXX Laboratories to Release 2017 Second Quarter Financial Results - July 10 at 7:43 PM logoAnalyzing Heska Corporation (HSKA) and IDEXX Laboratories (NASDAQ:IDXX) - July 8 at 2:18 PM logoIDEXX Laboratories (NASDAQ:IDXX) & Heska Corporation (HSKA) Financial Contrast - July 6 at 4:26 PM logoIDEXX Laboratories, Inc. (NASDAQ:IDXX) Downgraded by BidaskClub to "Buy" - July 5 at 8:38 PM logoIDEXX Laboratories, Inc. (IDXX) Given Consensus Rating of "Hold" by Analysts - June 30 at 9:39 AM logoGlobal biotech firm could create 100 Louisville jobs with new lab development - June 30 at 12:04 AM logoIDEXX Laboratories, Inc. (IDXX) Upgraded to "Buy" at Zacks Investment Research - June 29 at 12:52 AM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : June 28, 2017 - June 28 at 7:21 PM logoContrasting Heska Corporation (HSKA) and IDEXX Laboratories (IDXX) - June 28 at 7:52 AM logoMedidata (MDSO), inVentiv Enter Into Multi-Year Partnership - Nasdaq - June 27 at 6:02 PM logoMedidata (MDSO), inVentiv Enter Into Multi-Year Partnership - June 27 at 6:02 PM logoIDEXX Laboratories Stock Could Just Be Heating Up - June 27 at 6:02 PM logoIDEXX Laboratories, Inc. (IDXX) Downgraded by Zacks Investment Research to Hold - June 27 at 2:52 PM logoMerit Medical Embosphere Gets FDA de novo Classification - Nasdaq - June 27 at 5:50 AM logoMerit Medical Embosphere Gets FDA de novo Classification - June 26 at 7:38 PM logoHead to Head Comparison: IDEXX Laboratories (IDXX) versus Heska Corporation (HSKA) - June 25 at 7:54 AM logoZacks: Analysts Anticipate IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $500.78 Million - June 24 at 8:48 AM logoIDEXX Laboratories, Inc. (IDXX) Lifted to "Strong-Buy" at BidaskClub - June 23 at 8:20 PM logoIDEXX Laboratories, Inc. (IDXX) Expected to Announce Earnings of $0.83 Per Share - June 22 at 6:36 PM logoPRA Health Hits a 52-Week High on Strategic Acquisitions - June 22 at 1:18 PM logoNeogen Offers NeoSeek Genomic Services to Ensure Food Safety - June 20 at 6:43 PM logoPRA Health (PRAH) Shares Rally on Partnership with Jumo - June 20 at 6:43 PM logoTransEnterix Sells Surgery System to Japanese University - June 16 at 6:42 PM logoVarian Showcases Halcyon System at DEGRO Meet, Stock Up - June 16 at 6:42 PM logoPacific Biosciences (PACB) Prices Offering of Common Stock - June 16 at 6:42 PM logoIDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : June 14, 2017 - June 14 at 7:48 PM logoIDEXX Laboratories (IDXX) Presents At The William Blair 2017 Growth Stock Conference - Slideshow - June 14 at 11:29 AM logoBidaskClub Downgrades IDEXX Laboratories, Inc. (IDXX) to Buy - June 13 at 11:40 PM logoIDEXX Laboratories, Inc. (IDXX) Earns "Buy" Rating from Canaccord Genuity - June 13 at 5:18 PM logoIDEXX Laboratories, Inc. (IDXX) Raised to "Buy" at Zacks Investment Research - June 13 at 1:33 PM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : June 13, 2017 - June 13 at 10:59 AM logoZacks Investment Research Lowers IDEXX Laboratories, Inc. (IDXX) to Hold - June 12 at 11:10 AM



IDEXX Laboratories (IDXX) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff